JP2017528158A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528158A5
JP2017528158A5 JP2017524110A JP2017524110A JP2017528158A5 JP 2017528158 A5 JP2017528158 A5 JP 2017528158A5 JP 2017524110 A JP2017524110 A JP 2017524110A JP 2017524110 A JP2017524110 A JP 2017524110A JP 2017528158 A5 JP2017528158 A5 JP 2017528158A5
Authority
JP
Japan
Prior art keywords
seq
lentiviral vector
vector
antigen receptor
chimeric antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017524110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528158A (ja
JP6940406B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/067090 external-priority patent/WO2016012623A1/en
Publication of JP2017528158A publication Critical patent/JP2017528158A/ja
Publication of JP2017528158A5 publication Critical patent/JP2017528158A5/ja
Priority to JP2020156063A priority Critical patent/JP7341110B2/ja
Application granted granted Critical
Publication of JP6940406B2 publication Critical patent/JP6940406B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017524110A 2014-07-25 2015-07-24 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター Expired - Fee Related JP6940406B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020156063A JP7341110B2 (ja) 2014-07-25 2020-09-17 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462028889P 2014-07-25 2014-07-25
US62/028,889 2014-07-25
US201562155811P 2015-05-01 2015-05-01
US62/155,811 2015-05-01
EP15306036 2015-06-29
EP15306036.3 2015-06-29
PCT/EP2015/067090 WO2016012623A1 (en) 2014-07-25 2015-07-24 Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020156063A Division JP7341110B2 (ja) 2014-07-25 2020-09-17 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター

Publications (3)

Publication Number Publication Date
JP2017528158A JP2017528158A (ja) 2017-09-28
JP2017528158A5 true JP2017528158A5 (enExample) 2018-08-30
JP6940406B2 JP6940406B2 (ja) 2021-09-29

Family

ID=53514131

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017524110A Expired - Fee Related JP6940406B2 (ja) 2014-07-25 2015-07-24 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター
JP2020156063A Active JP7341110B2 (ja) 2014-07-25 2020-09-17 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター
JP2023078059A Withdrawn JP2023113656A (ja) 2014-07-25 2023-05-10 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020156063A Active JP7341110B2 (ja) 2014-07-25 2020-09-17 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター
JP2023078059A Withdrawn JP2023113656A (ja) 2014-07-25 2023-05-10 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター

Country Status (6)

Country Link
US (2) US10752668B2 (enExample)
EP (2) EP3511413B1 (enExample)
JP (3) JP6940406B2 (enExample)
CN (2) CN113846062B (enExample)
CA (1) CA2956385A1 (enExample)
WO (1) WO2016012623A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2817625B1 (en) 2012-02-23 2025-01-01 Juno Therapeutics GmbH Chromatographic isolation of cells and other complex biological materials
RU2761555C2 (ru) * 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
WO2017180587A2 (en) * 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN108276493B (zh) 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
CA3060526A1 (en) 2017-04-27 2018-11-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
US11220538B2 (en) 2017-05-01 2022-01-11 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
EP3697809A1 (en) 2017-10-20 2020-08-26 Institut Curie Dap10/12 based cars adapted for rush
US20200283485A1 (en) 2017-10-20 2020-09-10 Institut Curie Hook fusion protein for regulating the cellular trafficking of a target protein
AU2018362014A1 (en) 2017-11-03 2020-05-28 Sorrento Therapeutics, Inc. CD38-directed chimeric antigen receptor constructs
CA3088933A1 (en) 2018-01-17 2019-08-01 Aratinga Bio Tnp Polymer-encapsulated viral vectors for genetic therapy
EP3549597A1 (en) * 2018-04-06 2019-10-09 Heinrich-Heine-Universität Düsseldorf Synthetic signalling constructs and its use
US20210032661A1 (en) * 2018-04-09 2021-02-04 The Trustees Of The University Of Pennsylvania Methods And Compositions Comprising A Viral Vector For Expression Of A Transgene And An Effector
WO2019200056A2 (en) * 2018-04-12 2019-10-17 Vivo-Til Therapeutics Inc. Viral vectors and packaging cell lines
EP3999540A1 (en) * 2019-07-16 2022-05-25 Institut National de la Santé et de la Recherche Médicale (INSERM) Antibodies having specificity for cd38 and uses thereof
EP4028413A1 (en) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
GB201914611D0 (en) * 2019-10-09 2019-11-20 Autolus Ltd Engineered immune cell
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
US20230323394A1 (en) * 2020-09-01 2023-10-12 The Trustees Of The University Of Pennsylvania Improved generation of lentiviral vectors for t cell transduction using cocal envelope
US20240084354A1 (en) 2020-11-13 2024-03-14 Honing Biosciences Means and methods for regulating intracellular trafficking of secretory or cell membrane-anchored proteins of interest
IT202100011576A1 (it) * 2021-05-06 2022-11-06 Univ Degli Studi Padova Nuova sequenza promotore per terapia genica
US20240415951A1 (en) 2021-11-15 2024-12-19 Theravectys Lentiviral vector for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
CA3256704A1 (en) * 2022-05-23 2023-11-30 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR CRISPR SCREENING OF IMMUNE CELLS
IL318598A (en) 2022-07-27 2025-03-01 Theravectys Lentiviral vectors for the expression of human papillomavirus (HPV) antigens and their application in the treatment of HPV-induced cancer
US20250025158A1 (en) 2023-07-21 2025-01-23 Cilag Gmbh International Systems and subsystems for rolling a surgical instrument
EP4624494A1 (en) 2024-03-29 2025-10-01 Institut Curie Her2 single domain antibody and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP1026240A3 (en) 1988-09-02 2004-04-07 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE4135543A1 (de) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh Rekombinantes core-streptavidin
CN1367830A (zh) * 1998-10-05 2002-09-04 路德维哥癌症研究院 癌症相关抗原及其应用
EP2169073B1 (en) 1999-10-11 2013-11-13 Institut Pasteur Vector for the preparation of immunotherapeutical compositions
US6841359B2 (en) * 2000-10-31 2005-01-11 The General Hospital Corporation Streptavidin-binding peptides and uses thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2442739A1 (en) * 2001-04-03 2002-10-17 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
AU2002307625A1 (en) * 2002-03-08 2003-09-22 Cueros Industrializados Del Bajio Method of incorporating heat-stable particles into leather
US20050032173A1 (en) 2003-08-05 2005-02-10 Mauricio Rojas Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7265205B2 (en) * 2005-02-11 2007-09-04 Uti Limited Partnership Monomeric streptavidin muteins
JP2009529917A (ja) * 2006-03-22 2009-08-27 ヴァイラル ロジック システムズ テクノロジー コーポレーション 標的ポリペプチドの同定方法および免疫学的疾患の治療のためのその使用
WO2008105968A1 (en) 2006-11-03 2008-09-04 Smithkline Beecham Corporation Novel seh inhibitors and their use
EP2147683A1 (en) 2008-07-25 2010-01-27 DKFZ Deutsches Krebsforschungszentrum Construct and method for the internalization of cargo molecules into a cell
WO2010142785A1 (en) 2009-06-11 2010-12-16 Institut Curie Methods and kits for regulating intracellular trafficking of a target protein
EP3693017A1 (en) * 2010-12-14 2020-08-12 University of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
US9409987B2 (en) * 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
JP2015509717A (ja) * 2012-02-22 2015-04-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗腫瘍活性およびｃａｒ存続性を強化するためのｉｃｏｓベースのｃａｒの使用
BR112015002816A8 (pt) * 2012-08-20 2023-04-18 Hutchinson Fred Cancer Res Método e composições para imunoterapia celular
EP3763810A3 (en) * 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
RS61223B1 (sr) * 2013-12-20 2021-01-29 Hutchinson Fred Cancer Res Označeni himerni efektorski molekuli i njihovi receptori
GB2595063B (en) * 2015-07-31 2022-03-09 Univ Minnesota Modified cells and methods of therapy

Similar Documents

Publication Publication Date Title
JP2017528158A5 (enExample)
JP2016505635A5 (enExample)
JP2017537622A5 (enExample)
JP6816031B2 (ja) 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物
JP2019527055A5 (enExample)
JP2020074776A5 (enExample)
JP2016512557A5 (ja) 二重特異性分子及びそれを用いた方法
JP2015505299A5 (enExample)
JP2011530309A5 (enExample)
JP2014503206A5 (enExample)
JP2016501535A5 (enExample)
JP2015533841A5 (enExample)
JP2019509063A5 (enExample)
JP2015529678A5 (enExample)
MX375379B (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
JP2017538401A5 (enExample)
JP2013521789A5 (enExample)
FI3872085T3 (fi) Esimuotoiset virussekvenssit ja niiden käytöt
RU2015155821A (ru) Вакцины против малярии
RU2015153250A (ru) Cd19-специфический химерный антигенный рецептор и его применения
JP2012095652A5 (enExample)
JP2019519529A5 (enExample)
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
JP2015524422A5 (enExample)
RU2015135890A (ru) Композиция вакцины